A further recent study found that FSL was cost effective from a US payer perspective when added to glucagon-like peptide 1 receptor agonist therapies for the treatment of T2DM, including for patients not using intensive insulin (ICER, $40,968/QALY in the overall cohort; $43,095/QALY in the non-intensive insulin cohort) [61]. The gene discussed is INS; the disease is type 2 diabetes mellitus.